^
Association details:
| Biomarker: | AKT1 mutation + HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | sapanisertib (CB-228) (mTORC1 inhibitor, mTORC2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer
Published date:
04/05/2021
Excerpt:
Eligible patients had previously progressed on everolimus with exemestane/fulvestrant and received...Molecular analysis suggested positive association between AKT1 mutation status and best treatment response (complete+partial response; P = 0.0262)…. Sapanisertib plus exemestane or fulvestrant was well tolerated and exhibited clinical benefit...
Secondary therapy:
exemestane; fulvestrant
DOI:
10.1158/1078-0432.CCR-20-4131
